Xeris scores first FDA nod with shelf-stable glucagon injector

Xeris Pharmaceuticals made a $75 million bet last summer when it went public to back an FDA submission for its shelf-stable glucagon injector pen. Now, more than a year later, Xeris is ready to reap the rewards from that gambit.